This article has been cited by
1Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases
Kazuyo Shimada,Shiori Hasegawa,Satoshi Nakao,Ririka Mukai,Kiyoka Matsumoto,Mizuki Tanaka,Hiroaki Uranishi,Mayuko Masuta,Shohei Nishida,Shinya Shimizu,Yuichi Hayashi,Akio Suzuki,Mitsuhiro Nakamura
Cancer Chemotherapy and Pharmacology.2019;84(5)1097
[DOI]
2Neurological Complications of the Treatment of Pediatric Neoplastic Disorders
Lisa R. Sun,Stacy Cooper
Pediatric Neurology.2018;85(5)33
[DOI]
3Neurological Complications of the Treatment of Pediatric Neoplastic Disorders
Kirby Welston,Dianne May
Pediatric Neurology.2018;40(5)463
[DOI]
4Fosaprepitant/ifosfamide interaction
Kirby Welston,Dianne May
Reactions Weekly.2017;1652(1)142
[DOI]
5Ifosfamide-induced encephalopathy: Brand-name (HOLOXAN®) vs generic formulation (IFOSFAMIDE EG®)
Jeremy Chambord,Fabien Henny,Julia Salleron,Benoit Hombourger,Pauline Lider,Jean Vigneron,Beatrice Demore,Catherine Vallance,Maria Rios
Journal of Clinical Pharmacy and Therapeutics.2019;44(3)372
[DOI]
  Feedback 
  Subscribe